

Surrey & North West Sussex Area Prescribing Committee

Policy Statement	Patiromer for the treatment of hyperkalaemia in adults (NICE TA 623)
Policy No:	APC 491-2020
Date of Issue	August 2020
Review Date:	<i>The recommendation made by the APC can be reviewed prior to the review date when new published evidence or national guidance becomes available. A review can be requested via email to the APC secretary. No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal</i>
Recommendations: <p>The Surrey & North West Sussex Area Prescribing Committee recommends Patiromer as a treatment option for the treatment of Hyperkalaemia in adults in line with NICE TA623 in</p> <ul style="list-style-type: none"> • emergency care for acute life threatening hyperkalaemia or • * for patients with persistent hyperkalaemia (in line with NICE thresholds) <p>Patiromer will be considered RED on the traffic light system in all cases.</p> <p>Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.</p>	
Key Considerations: <ul style="list-style-type: none"> • NICE TA623 Patiromer for the treatment of hyperkalaemia in adults (Feb 2020) https://www.nice.org.uk/guidance/ta623/resources/patiromer-for-treating-hyperkalaemia-pdf-82609015577029 • * Monitoring or dose adjustment advice unavailable – Primary care prescribing not currently appropriate for persistent hyperkalaemia; awaiting study on longer-term use 	
Date taken to Area Prescribing Committee	3 rd August 2020
Agreed by APC members	10th August 2020

Surrey Integrated Care Partnerships (ICPs) (East Surrey, Surrey Downs, Guildford & Waverley, North West Surrey) North West Sussex ICPs (Crawley, Horsham & Mid Sussex) & associated partner organisations